Marker May Predict Immunotherapy Benefit in High-Risk Neuroblastoma
This video examines how a specific combination of KIR/KIR-ligand genotypes in high-risk neuroblastoma patients may be predictive of outcomes when adding dinutuximab to isotretinoin.